Latest news with #A1c
Medscape
22-05-2025
- Health
- Medscape
Seniors With Diabetes Benefit From Intermittent Scanning CGM
The use of intermittent scanning continuous glucose monitoring (is-CGM) led to significant reductions in A1c levels among patients aged 60 years or older with type 1 or type 2 diabetes, with improvements visible after 3 months and persisting up to 24 months. The technology showed high acceptance among users, with only 2.8% discontinuing it due to device-related issues. METHODOLOGY: Although real-time CGM has shown effectiveness in improving glycaemic control and preventing hypoglycaemia in older adult patients, the efficacy of is-CGM remains understudied in this population. Researchers in the Netherlands conducted a retrospective case-control study to compare reductions in A1c levels between patients aged 60 years or older with type 1 or insulin-dependent type 2 diabetes who used is-CGM and those who did not. They selected 353 patients (median age, 67 years; 59.8% men) from an outpatient clinic in Groningen; those who used is-CGM (n = 142) were matched with control individuals (n = 211) who did not use is-CGM on the basis of age, sex, type of diabetes, and insulin treatment modality. Data were collected at baseline and 3, 6, 9, 12, and 24 months following the initiation of is-CGM, focusing on A1c levels and sensor usage. The primary endpoint was the difference in A1c levels over time between is-CGM users and control individuals relative to their baseline values. TAKEAWAY: Median baseline A1c levels were 7.9% and 7.8% among is-CGM users and control individuals, respectively. After 3 months of initiating is-CGM, a significant reduction in A1c levels was observed among users compared with control individuals (unadjusted estimates, −0.5% vs −0.01%; P = .013), with reductions persisting throughout the study. = .013), with reductions persisting throughout the study. After accounting for potential confounders, initiating is-CGM led to persistent statistically significant reductions in A1c levels at 6 months (−0.46%; P = .006) and 24 months (−0.39%; P = .033). = .006) and 24 months (−0.39%; = .033). Device acceptance was notably high, with only 2.8% of users discontinuing is-CGM due to device-related reasons. No cases of diabetes-related complications were seen in both the groups. IN PRACTICE: "Together with the minimal number of discontinuations due to device-related reasons, our findings argue for the use of this technology in the elderly (60+) population with DM [diabetes mellitus]," the authors wrote. SOURCE: This study was led by Riemer A. Been, MD, University Medical Center Groningen, Groningen, the Netherlands. It was published online on May 13, 2025, in Diabetes, Obesity and Metabolism . LIMITATIONS: The distribution of patients with type 1 diabetes was not evenly balanced between control and is-CGM groups. The study defined older adults as those aged 60 years or older, which may not have adequately reflected the diversity within this population, especially since those aged 80 years or older were underrepresented. The single-centre design at an academic hospital in the Netherlands may have limited the generalisability of the results to other regions. DISCLOSURES: This study was funded by the European Foundation for the Study of Diabetes. One author reported receiving an unrestricted educational grant from the European Foundation for the Study of Diabetes mentorship programme supported by AstraZeneca. The remaining authors reported having no conflicts of interest.
Medscape
09-05-2025
- Health
- Medscape
Cataract Surgery May Be Safe Beyond A1c Cutoffs
Cataract surgery was not associated with an increased risk for postoperative endophthalmitis or serious systemic adverse events in patients with diabetes, even when preoperative A1c levels were poorly controlled and exceeded 11.3%. METHODOLOGY: Researchers conducted a retrospective, longitudinal cohort study to explore the relationship between cataract surgery and the risk for postoperative endophthalmitis and serious systemic adverse events in patients with diabetes. They examined medical records of 94,952 men and women, aged 18 years or older, with type 1 or type 2 diabetes who underwent phacoemulsification cataract surgery and were stratified by A1c levels: Good (< 7%), moderate (7%-8.4%), poor (8.5%-11.3%), and very poor (> 11.3%) control. Patients in each group of A1c levels were matched by propensity score analysis with individuals without diabetes who underwent cataract surgery. To analyze the risk for serious systemic adverse events — mortality, stroke, transient ischemic attack, major cardiovascular events, and a composite of these events — the researchers compared 12,835 patients with diabetes who underwent cataract surgery with those who had similar A1c levels and a record of a routine eye examination but did not undergo the procedure. In both analyses, A1c documentation was required to have occurred within 3 months prior to cataract surgery. TAKEAWAY: The 30-day risk for postoperative endophthalmitis did not differ across A1c levels between patients with diabetes and people without the condition (good control: hazard ratio [HR], 0.62; 95% CI, 0.30-1.27; moderate control: HR, 1.08; 95% CI, 0.44-2.66; poor control: HR, 1.36; 95% CI, 0.43-4.28; and very poor control: HR, 2.85; 95% CI, 0.29-27.44). Similarly, the risk for serious systemic adverse events within 30 or 90 days after cataract surgery showed no difference across A1c levels in patients with diabetes who did or did not undergo cataract surgery. IN PRACTICE: 'Our findings suggest that preoperative A1c alone should not be a reason to cancel cataract surgery,' the authors wrote. 'A1c should be utilized as measure to inform wider control of hyperglycemia- and diabetes-related systemic comorbidities and that delaying cataract surgery on the numerical basis of elevated A1c is not necessary,' they added. SOURCE: This study was led by Zain S. Hussain, MD, and Ahmed F. Shakarchi, MD, MPH, from the Harvey and Bernice Jones Eye Institute at the University of Arkansas for Medical Sciences in Little Rock, Arkansas. It was published online on May 3, 2025, in American Journal of Ophthalmology . LIMITATIONS: The retrospective design limited the ability of this study to infer causality. Small sample sizes in certain subgroups of A1c resulted in wide CIs for some outcomes, potentially limiting the precision of findings. The control group of patients with diabetes who did not have a diagnosis of cataract may have been healthier, introducing selection bias. DISCLOSURES: No funding was reported by this study. The authors reported having no relevant conflicts of interest.
Yahoo
11-02-2025
- Business
- Yahoo
Hemoglobin A1c Testing Devices Market Accelerates: Unlocking a US$3.3 Billion Revolution in Diabetes Diagnostics by 2034 – Latest Report by TMR
The Hemoglobin A1c Testing Devices Market is experiencing significant growth due to rising diabetes prevalence, advancements in diagnostic technology, and increasing awareness of diabetes management. Key players are focusing on innovation and strategic partnerships to enhance accessibility and accuracy in testing. Emerging markets present lucrative opportunities for expansion, particularly in point-of-care testing solutions. Wilmington, Delaware, Transparency Market Research Inc. –, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The global Hemoglobin A1c Testing Devices Market (Marché des Dispositifs de Test de l'Hémoglobine A1c) was valued at US$ 1.4 billion in 2023 and is projected to expand at a CAGR of 7.7% from 2024 to 2034, reaching more than US$ 3.3 billion by the end of 2034. The demand for hemoglobin A1c (HbA1c) testing devices is rising significantly due to the growing prevalence of diabetes, advancements in diagnostic technology, and increasing awareness regarding diabetes management. Decision-makers in the healthcare and pharmaceutical industries are investing heavily in diagnostic solutions that offer rapid, precise, and efficient HbA1c testing to support early detection and effective diabetes management. Get the Report Sample upon Request: Landscape The Hemoglobin A1c Testing Devices Market is highly competitive, with the presence of several global and regional players. Key players include: Abbott (Alere Technologies AS) GC Medical Science Corp. Osang Healthcare Co., Ltd. EKF Diagnostics Holdings Boditech Med Inc. Roche Diagnostics (F. Hoffmann-La Roche Ltd.) Eurolyser Diagnostica GmbH Bayer AG Siemens Healthineers AG These companies are focusing on innovation, product development, and strategic partnerships to strengthen their market position. Strategies Adopted by Key Players Product Innovation – Companies are investing in the development of next-generation HbA1c testing devices with faster results, improved accuracy, and wireless connectivity. Expansion into Emerging Markets – With diabetes cases rising in Asia-Pacific, Latin America, and Africa, companies are expanding their presence in these regions. Acquisitions and Partnerships – Mergers and collaborations with healthcare providers and research institutions are helping companies strengthen their product offerings. Integration with Digital Health Solutions – The adoption of AI-powered data analytics and cloud-based monitoring in HbA1c testing devices is improving diabetes care. Key Development Of Companies- 1. Abbott Laboratories (2023): Abbott expanded its FreeStyle Libre portfolio with the launch of the FreeStyle Libre 3 system, a continuous glucose monitoring (CGM) device that provides real-time glucose readings. This system offers a more comprehensive approach to diabetes management, complementing HbA1c testing. 2. Siemens Healthineers (2023): Siemens Healthineers introduced the Atellica VTLi Hemoglobin A1c Analyzer, designed to deliver high-throughput, accurate HbA1c testing. This analyzer aims to improve laboratory efficiency and support better patient outcomes. Key Drivers in Hemoglobin A1c Testing Devices Market 1. Increasing Diabetes Prevalence The rise in diabetes cases worldwide is a primary driver of the HbA1c testing devices market. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2023, and this number is expected to increase significantly over the next decade. As diabetes remains a leading cause of mortality and morbidity, regular monitoring of HbA1c levels has become crucial in disease management. 2. Advancements in Diagnostic Technologies Manufacturers are continuously innovating to develop faster, more accurate, and easy-to-use testing devices. Some of the major advancements include: Portable point-of-care testing (POCT) devices that allow real-time monitoring Integration of AI and cloud-based analytics for accurate result interpretation Development of non-invasive testing techniques to improve patient compliance 3. Growing Awareness & Preventive Healthcare Initiatives Public health campaigns, government programs, and rising healthcare spending are increasing awareness about the importance of HbA1c testing in managing diabetes. Regular HbA1c monitoring is now recommended by the American Diabetes Association (ADA) and other global health organizations as a crucial tool for assessing long-term glucose control. Request Customization to Get Tailored Insights for Your Business Needs: Market Challenges High Cost of Advanced Testing Devices Despite technological advancements, the high cost of automated and AI-integrated HbA1c testing devices limits their adoption in lower-income regions. This challenge is particularly significant in emerging economies where healthcare budgets are constrained. Lack of Standardization in HbA1c Testing Differences in testing methodologies across laboratories can lead to variability in results, affecting the accuracy of diabetes diagnosis and treatment. This necessitates stricter regulatory compliance and standardization of testing procedures. Limited Access in Rural & Underserved Areas The availability of diagnostic facilities in remote and rural areas remains a challenge. Limited access to healthcare services and diagnostic centers delays diabetes diagnosis, leading to higher disease complications and healthcare costs. Investment Opportunities in Hemoglobin A1c Testing Devices Industry 1. Expansion of Point-of-Care (POC) Testing Devices The rising demand for rapid, real-time HbA1c testing presents a major growth opportunity for POC testing device manufacturers. Investments in miniaturized, handheld, and portable testing devices can enhance accessibility in both urban and rural settings. 2. Strategic Partnerships & Mergers Key players are increasingly forming strategic collaborations with hospitals, diagnostic labs, and research institutions to expand their market presence. Partnerships with government and non-profit organizations can also enhance affordable access to HbA1c testing devices. 3. Growing Market in Emerging Economies Developing regions such as Asia Pacific, Latin America, and the Middle East & Africa are witnessing a surge in diabetes cases and healthcare infrastructure development. Market players can capitalize on this trend by offering cost-effective solutions tailored to the needs of these regions. Market Segmentation By Technology Cation-exchange Chromatography Immunoassay Boronate Affinity Chromatography Others (Enzymatic assay, etc.) By Modality Automated Semi-automated By End-user Hospitals Diagnostic Laboratories Ambulatory Surgical Centers Others (Specialty Clinics, Academic & Research Institutes, etc.) By Region North America Europe Asia Pacific Latin America Middle East & Africa Future Outlook The Hemoglobin A1c Testing Devices Market is poised for strong growth, driven by increasing diabetes prevalence, advancements in diagnostic technology, and rising awareness of diabetes management. North America and Europe currently dominate the market, while Asia Pacific presents the highest growth potential. Key investment opportunities lie in point-of-care testing innovations, strategic partnerships, and market expansion in developing regions. As healthcare providers and pharmaceutical companies continue to prioritize early and accurate diabetes diagnosis, the demand for advanced HbA1c testing devices will continue to rise. Buy This Premium Research Report Now to Get Detailed Analysis: Why This Report is Useful for Decision Makers and Investors Identifies Market Growth Opportunities – Investors can explore high-potential segments within the HbA1c testing market. Helps in Competitive Analysis – Understanding key players and their strategies assists businesses in making informed decisions. Provides Market Forecasts – Future projections help stakeholders plan their investments and business strategies. Supports Product Development Strategies – Insights into emerging technologies guide companies in developing innovative HbA1c testing solutions. Enhances Business Expansion Strategies – Companies can use regional analysis to target new markets and optimize global expansion. Explore Latest Research Reports by Transparency Market Research: Spot Check Monitors Market - Projected to grow at a CAGR of 7.3% from 2024 to 2034 and cross US$ 7.4 Bn by the end of 2034. Biodegradable Stents Market - Expected to grow at a CAGR of 7.8% from 2024 to 2034 and reach US$ 809.2 Mn by the end of 2034. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA – Canada Toll Free: 866-552-3453Website: Email: sales@ Us: LinkedIn| Twitter| Blog | YouTubeSign in to access your portfolio
